Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.

[1]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[2]  A. Plesa,et al.  Prognostic Value of Immunophenotyping in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. , 2007 .

[3]  R. Arceci,et al.  Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. , 2007, Blood.

[4]  C. Segeren,et al.  AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients , 2005, Annals of Hematology.

[5]  Claudia Schoch,et al.  Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients , 2001, British journal of haematology.

[6]  N. Fineberg,et al.  Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). , 2000, American journal of clinical pathology.

[7]  A. Carella,et al.  Minimally Differentiated Acute Myeloid Leukemia (AML M0): Clinico-Biological Findings of 29 Cases , 2000, Leukemia & lymphoma.

[8]  W. Tsay,et al.  Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years , 1999, Leukemia.

[9]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[10]  E. Montserrat,et al.  Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics , 1998, Leukemia.

[11]  G. Dewald,et al.  Acute myeloid leukemia with minimal differentiation. A multiple parameter study. , 1998, American journal of clinical pathology.

[12]  G. Papa,et al.  Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. , 1997, Blood.

[13]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.

[14]  P. Cin,et al.  Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. , 1995, Blood.

[15]  Segeren Cm,et al.  AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults. , 1995 .

[16]  M. B. van 't Veer,et al.  AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults. , 1995, Annals of hematology.

[17]  M. Tribalto,et al.  Minimally differentiated acute myeloid leukaemia (AML‐MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases , 1994, British journal of haematology.

[18]  G. Papa,et al.  Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). , 1994, Blood.

[19]  M. Sanz,et al.  Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. , 1993, Leukemia & lymphoma.

[20]  C. Bloomfield,et al.  Trisomy 13 in acute leukemia. , 1992, Leukemia & lymphoma.

[21]  F. Mitelman.  ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .

[22]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[23]  A. Sandberg,et al.  Trisomy/tetrasomy 13 in seven cases of acute leukemia. , 1990, Leukemia.

[24]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Treille,et al.  Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy , 1989, British journal of haematology.

[26]  J. Testa,et al.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. , 1987, Blood.